BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman Sells 956 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 956 shares of the company’s stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $15.31, for a total value of $14,636.36. Following the sale, the chief financial officer now directly owns 126,658 shares in the company, valued at approximately $1,939,133.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Troy Wichterman also recently made the following trade(s):

• On Thursday, March 21st, Troy Wichterman sold 520 shares of BioLife Solutions stock. The stock was sold at an average price of $17.83, for a total value of $9,271.60.
• On Monday, March 11th, Troy Wichterman sold 361 shares of BioLife Solutions stock. The stock was sold at an average price of $17.42, for a total value of $6,288.62.
• On Wednesday, February 21st, Troy Wichterman sold 97 shares of BioLife Solutions stock. The stock was sold at an average price of $17.35, for a total value of $1,682.95.

BioLife Solutions Stock Performance

NASDAQ:BLFS opened at $17.02 on Wednesday. The firm has a market capitalization of $771.01 million, a PE ratio of -11.20 and a beta of 1.67. The business’s fifty day moving average price is $17.40 and its 200 day moving average price is $15.39. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.86 and a quick ratio of 1.83. BioLife Solutions, Inc. has a 12 month low of $8.92 and a 12 month high of $24.50.

BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Thursday, February 29th. The medical equipment provider reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.02. The firm had revenue of $32.73 million for the quarter, compared to analyst estimates of $32.70 million. BioLife Solutions had a negative return on equity of 13.36% and a negative net margin of 46.37%. On average, sell-side analysts anticipate that BioLife Solutions, Inc. will post -0.6 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group started coverage on BioLife Solutions in a research report on Thursday, April 4th. They set a “buy” rating and a $22.00 price objective on the stock. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $23.40.

Hedge Funds Weigh In On BioLife Solutions

Several large investors have recently bought and sold shares of BLFS. Allspring Global Investments Holdings LLC grew its holdings in shares of BioLife Solutions by 161,879.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 131,203 shares of the medical equipment provider’s stock worth $2,434,000 after purchasing an additional 131,122 shares during the last quarter. Register Financial Advisors LLC purchased a new position in shares of BioLife Solutions during the first quarter worth about $96,000. Goldman Sachs Group Inc. grew its holdings in shares of BioLife Solutions by 1,038.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,401,899 shares of the medical equipment provider’s stock worth $39,031,000 after purchasing an additional 2,191,002 shares during the last quarter. Granahan Investment Management LLC grew its holdings in shares of BioLife Solutions by 22.8% during the fourth quarter. Granahan Investment Management LLC now owns 1,292,675 shares of the medical equipment provider’s stock worth $21,006,000 after purchasing an additional 240,001 shares during the last quarter. Finally, Ranger Investment Management L.P. grew its holdings in shares of BioLife Solutions by 6.7% during the fourth quarter. Ranger Investment Management L.P. now owns 363,574 shares of the medical equipment provider’s stock worth $5,908,000 after purchasing an additional 22,906 shares during the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.